Exact Sciences Announces Prelim Q4 Results

 Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fourth quarter ended Dec. 31, 2020.

"I'm incredibly proud of how the Exact Sciences team came together during 2020 to make progress towards our mission of eradicating cancer and the suffering it causes," said Kevin Conroy, chairman and CEO of Exact Sciences. "Following our combination with Thrive, we are confident in making blood-based, multi-cancer screening a reality and being a leading provider of earlier, smarter cancer tests for patients at every step of their journey. We've never been more excited about the impact Exact Sciences will have on patient lives with Cologuard, Oncotype, and our future tests."

Preliminary, Unaudited Fourth Quarter 2020 Financial Results

For the three-month period ended December 31, 2020, as compared to the same period of 2019 (where applicable):

• Expected total revenue between $464.5 million and $467.5 million
• Expected Screening revenue between $249 million and $250 million, an increase of 9 percent
• Expected Precision Oncology revenue between $117 million and $118 million
• Expected COVID-19 testing revenue between $98.5 million and $99.5 million

Preliminary, Unaudited 2020 Financial Results

For the twelve-month period ended December 31, 2020, as compared to the same period of 2019 (where applicable):

• Expected total revenue between $1.490 billion and $1.493 billion
• Expected Screening revenue between $814.5 million and $815.5 million, an increase of 1 percent
• Expected Precision Oncology revenue between $440 million and $441 million
• Expected COVID-19 testing revenue between $235 million and $236 million

For the fourth quarter and 2020, Screening includes laboratory service revenue from Cologuard and revenue from Biomatrica products. Precision Oncology includes laboratory service revenue from global Oncotype products.

Exact Sciences has not completed preparation of its financial statements for the fourth quarter or full year of 2020. The revenue ranges presented in this news release for the fourth quarter of 2020 and for the year ended Dec. 31, 2020 are preliminary and unaudited and are thus inherently uncertain and subject to change as we complete our financial results for the fourth quarter of 2020. Exact Sciences is in the process of completing its customary year-end close and review procedures as of and for the year ended Dec. 31, 2020, and there can be no assurance that final results for this period will not differ from these estimates. During the course of the preparation of Exact Sciences' consolidated financial statements and related notes as of and for the year ended Dec. 31, 2020, the company's independent registered public accountants may identify items that could cause final reported results to be materially different from the preliminary financial estimates presented herein.

Exact Sciences plans to report 2020 financial results during its February 2021 earnings call.

https://www.streetinsider.com/PRNewswire/Exact+Sciences+Announces+Preliminary+Fourth+Quarter+2020+Results/17803845.html